Picture loading failed.

Anti-CLDN18 therapeutic antibody (Pre-made Claudiximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-109-1mg 1mg 3090
GMP-Bios-ab-109-10mg 10mg 21890
GMP-Bios-ab-109-100mg 100mg 148000
GMP-Bios-ab-109-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CLDN18 therapeutic antibody (Pre-made Claudiximab biosimilar,Whole mAb)
INN Name Claudiximab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesGanymed Pharmaceuticals
Conditions Approvedna
Conditions ActiveGastric cancer;Oesophageal cancer;Pancreatic cancer
Conditions DiscontinuedSolid tumours
Development Techna